Shreyas Joshi, MD, MPH

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (221 ratings)

Role

Urology
Specialty

Bladder Cancer Kidney (Renal) Cancer Prostate Cancer Penile Cancer Testicular Cancer Adrenal Cancer
Research Program

Cancer Prevention and Control
Practicing Since

2018

Call 404-778-4898

Background

Shreyas S. Joshi, MD, MPH, is an Assistant Professor in the Department of Urology at the Emory University School of Medicine. Dr. Joshi serves as the Acting Director of the Bladder Cancer Program. A board certified urologist, his clinical interests include the management of complex urologic malignancies, with particular specialization in open, laparoscopic, and robotic approaches to prostate, bladder, and kidney cancers, as well as the surgical management of other urologic cancers. Prior to joining Emory in 2019, Dr. Joshi was an attending surgeon at Fox Chase Cancer Center.
Dr. Joshi is a member and active participant in the American Urological Association and the Society of Urologic Oncology.

Dr. Joshi earned his MD from Indiana University School of Medicine in Indianapolis, Indiana. He completed his general surgery internship and urology residency at Vanderbilt University Medical Center in Nashville, Tennessee. He completed his Society of Urologic Oncology Fellowship at Fox Chase Cancer Center in Philadelphia, and obtained his Master of Public Health at Temple University College of Public Health.

Dr. Joshi's research interests include:

Health outcomes research focused on urologic oncology
Quality improvement initiatives in surgical care, specifically related to curbing the opioid epidemic
Access to quality surgical care, particularly improving screening and treatment for minorities with urologic diseases
Global surgical health, primarily in the areas of comparative effectiveness in cancer surgery and surgical disparities research
Machine learning applications to urologic oncology

Dr. Joshi has published, contributed, and presented dozens of abstracts, articles, and book chapters on urologic cancers, and actively participates in major national clinical trials.
PubMed

Titles & Roles

Assistant Professor, Department of Urology

Emory University School of Medicine
Director, Bladder Cancer Program, Department of Urology

Emory University School of Medicine

Education & Training

Education

Fellowship, Urology, 2018
Fox Chase Cancer Center
Residency, Urology, 2016
Vanderbilt University Medical Center
Internship, General Surgery, 2012
Vanderbilt University Medical Center
Medical Education, MD, 2011
Indiana University School of Medicine

Research

View Current Clinical Trials


LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve Phase I/II Conditions Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ Location Winship Cancer Institute
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Phase III Conditions Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer Location Winship Cancer Institute
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Phase III Conditions Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8 Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Grady Health System, Winship Cancer Institute
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma Phase II Conditions Lymphadenopathy, Stage I Testicular Seminoma, Stage II Testicular Seminoma Location Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes. American journal of clinical pathology	KB Case, DJ Martini, MN Dababneh, S Bidot, B Nazha, J Brown, S Joshi, V Narayan, V Parihar, F Saeed, MA Bilen, LR Harik	04/19/2025
Incidence of New Mental Health Diagnosis in Testicular Cancer Survivors. Urology	S Marthi, G Palmateer, T Helman, D Patil, E Nicaise, T Goodstein, K Ogan, V Narayan, V Master, SS Joshi	04/16/2025
A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy. BJU international	JJ de Jong, JA Proudfoot, S Daneshmand, RS Svatek, V Narayan, EA Gibb, E Davicioni, S Joshi, A Dahmen, R Li, BA Inman, P Shah, I Chaplin, J Wright, Y Lotan	04/01/2025
Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States. Cancer	NT Sebastian, D Patil, PR Patel, AB Jani, BW Hershatter, VR Dhere, KD Godette, CA Lorentz, AD Weiss, SS Joshi, MG Sanda, SA Patel	03/15/2025
Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy. European urology open science	JJ de Jong, JA Proudfoot, S Daneshmand, RS Svatek, V Narayan, E Davicioni, S Joshi, A Dahmen, R Li, BA Inman, P Shah, I Chaplin, J Wright, EA Gibb, Y Lotan	03/01/2025
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. Nature cancer	MA Bilen, BT Vo, Y Liu, R Greenwald, AH Davarpanah, D McGuire, R Shiradkar, L Li, A Midya, B Nazha, JT Brown, S Williams, W Session, G Russler, S Caulfield, SS Joshi, VM Narayan, CP Filson, K Ogan, O Kucuk, BC Carthon, L Del Balzo, A Cohen, A Boyanton, N Prokhnevska, MA Cardenas, E Sobierajska, CS Jansen, DH Patil, E Nicaise, AO Osunkoya, HT Kissick, VA Master	03/01/2025
Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades. Clinical genitourinary cancer	BD Hopkins, DC Qian, KM Xu, A McCook-Veal, J Switchenko, LM Hartsell, CB Cimmino, SS Joshi, V Narayan, VA Master, B Nazha, BC Carthon, MA Bilen, O Kucuk, JW Shelton, PR Patel, AB Jani, JS Remick, TY Eng	02/01/2025
Paraneoplastic Syndrome Prevalence and Survival in Racially-Diverse Cohort With Renal Cell Carcinoma. Clinical genitourinary cancer	EH Nicaise, BN Schmeusser, G Palmateer, K Vashi, K Parikh, D Patil, DD Shapiro, EJ Abel, S Joshi, V Narayan, K Ogan, VA Master	12/01/2024
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer. Nature	MA Cardenas, N Prokhnevska, E Sobierajska, P Gregorova, CB Medina, RM Valanparambil, R Greenwald, L DelBalzo, MA Bilen, SS Joshi, VM Narayan, VA Master, MG Sanda, HT Kissick	12/01/2024
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation. Cancer	DJ Martini, KB Case, D Gratz, K Pellegrini, E Beagle, T Schneider, M Dababneh, B Nazha, JT Brown, SS Joshi, VM Narayan, K Ogan, VA Master, BC Carthon, O Kucuk, LR Harik, MA Bilen	11/01/2024
Paraneoplastic Resolution Holds Prognostic Utility in Patients with Metastatic Renal Cell Carcinoma. Cancers	G Palmateer, EH Nicaise, T Goodstein, BN Schmeusser, D Patil, N Imtiaz, DD Shapiro, EJ Abel, S Joshi, V Narayan, K Ogan, VA Master	10/30/2024
Building a machine learning-assisted echocardiography prediction tool for children at risk for cancer therapy-related cardiomyopathy. Cardio-oncology (London, England)	LA Edwards, C Yang, S Sharma, ZH Chen, L Gorantla, SA Joshi, NJ Longhi, N Worku, JS Yang, B Martinez Di Pietro, S Armenian, A Bhat, W Border, S Buddhe, N Blythe, K Stratton, KJ Leger, WM Leisenring, LR Meacham, PC Nathan, S Narasimhan, R Sachdeva, K Sadak, EJ Chow, PM Boyle	10/09/2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial. Research square	MA Bilen, BT Vo, Y Liu, R Greenwald, AH Davarpanah, D McGuire, R Shiradkar, L Li, B Nazha, JT Brown, S Williams, W Session, G Russler, S Caulfield, SS Joshi, VM Narayan, CP Filson, K Ogan, O Kucuk, BC Carthon, L Del Balzo, A Cohen, A Boyanton, N Prokhnevska, MA Cardenas, E Sobierajska, CS Jansen, DH Patil, E Nicaise, AO Osunkoya, H Kissick, VA Master	08/08/2024
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy. Clinical genitourinary cancer	EH Nicaise, BN Schmeusser, A Ali, E Midenberg, AR Palacios, B Hartsoe, E Kearns, S Ambadi, DH Patil, SS Joshi, VM Narayan, SP Psutka, B Nazha, JT Brown, K Ogan, MA Bilen, VA Master	06/01/2024
2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race. Cancer	BN Schmeusser, DH Patil, EH Nicaise, M Armas-Phan, R Nabavizadeh, VM Narayan, SS Joshi, K Ogan, AO Osunkoya, MA Bilen, VA Master	02/01/2024
Let's Be Practical: Home-based Moderate-intensity Exercise Interventions Are Needed. European urology focus	S Parke, S Joshi	01/01/2024
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study. International urology and nephrology	J Hafron, BN Breyer, S Joshi, C Smith, MR Kaufman, J Okonski, MB Chancellor	01/01/2024
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker. The oncologist	BN Schmeusser, H Biermann, EH Nicaise, AA Ali, DH Patil, E Midenberg, T Helman, M Armas-Phan, R Nabavizadeh, SS Joshi, VM Narayan, MA Bilen, SP Psutka, K Ogan, VA Master	12/11/2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors. The oncologist	GE Sanda, JM Shabto, S Goyal, Y Liu, DJ Martini, B Nazha, JT Brown, LB Yantorni, G Anne Russler, S Caulfield, SS Joshi, VM Narayan, H Kissick, K Ogan, VA Master, BC Carthon, O Kucuk, MA Bilen	12/11/2023
Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus. Clinical genitourinary cancer	BN Schmeusser, E Midenberg, AR Palacios, AA Ali, DH Patil, M Higgins, R Nabavizadeh, B Croll, M Williams, J Sheehy, B Zheng, VM Narayan, SS Joshi, K Ogan, SP Psutka, MA Bilen, VA Master	08/01/2023
Prolonged Opioid Use Following Bladder Tumor Resection for Opioid-naïve Patients. Urology practice	B Croll, D Patil, M Mason, VM Narayan, V Master, CP Filson, SS Joshi	07/01/2023
What's in a Name: An Analysis of Gender-Based Acronyms in Clinical Trials. Annals of surgical oncology	L Bukavina, M Sindhani, SS Joshi, E Plimack, A Correa, N Uzzo, A Kutikov, R Uzzo	05/01/2023
Editorial Comment. The Journal of urology	B Croll, SS Joshi	05/01/2023
Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy. Clinical nuclear medicine	IO Lawal, C Marcus, DM Schuster, S Goyal, OA Adediran, VR Dhere, SS Joshi, OA Abiodun-Ojo, VA Master, PR Patel, B Fielder, M Goodman, JW Shelton, O Kucuk, B Hershatter, RK Halkar, AB Jani	04/01/2023
Clinicopathologic analysis of patients undergoing repeat transurethral resection of bladder tumour following an initial diagnosis of urothelial carcinoma with lamina propria invasion and variant/divergent histology. Journal of clinical pathology	P Mullane, S Joshi, M Bilen, AO Osunkoya	04/01/2023
Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus ¹⁸F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial. Journal of nuclear medicine : official publication, Society of Nuclear Medicine	IO Lawal, AB Jani, OA Adediran, S Goyal, OA Abiodun-Ojo, VR Dhere, CV Marcus, SS Joshi, VA Master, PR Patel, M Goodman, JW Shelton, O Kucuk, B Hershatter, B Fielder, RK Halkar, DM Schuster	04/01/2023
CD8⁺ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity	N Prokhnevska, MA Cardenas, RM Valanparambil, E Sobierajska, BG Barwick, C Jansen, A Reyes Moon, P Gregorova, L delBalzo, R Greenwald, MA Bilen, M Alemozaffar, S Joshi, C Cimmino, C Larsen, V Master, M Sanda, H Kissick	01/10/2023
Challenges and opportunities in the management of non-urothelial bladder cancers. Cancer treatment and research communications	JT Brown, VM Narayan, SS Joshi, L Harik, AB Jani, MA Bilen	01/01/2023
Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Cancer	AI Khan, SP Psutka, DH Patil, G Hong, MA Williams, MA Bilen, A Sekhar, HT Kissick, VM Narayan, SS Joshi, K Ogan, VA Master	06/01/2022
Histopathologic findings in patients who have undergone blue light cystoscopy and bladder biopsy or transurethral resection: A contemporary clinicopathologic analysis of 100 cases. Pathology, research and practice	J Singh, S Farooq, S Joshi, AO Osunkoya	06/01/2022
Exosomal Metabolic Signatures Are Associated with Differential Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. International journal of molecular sciences	S Joshi, C Garlapati, S Bhattarai, Y Su, L Rios-Colon, G Deep, MA Torres, R Aneja	05/10/2022
Editorial Comment. The Journal of urology	B Croll, SS Joshi	05/01/2022
Editorial Commentary. Urology practice	SR Donnenfeld, SS Joshi	05/01/2022
A Contemporary Clinicopathologic Analysis of Primary Urothelial Carcinoma of the Urethra Without Concurrent Renal Pelvic, Ureteral, or Bladder Carcinoma. International journal of surgical pathology	F Chen, S Joshi, BC Carthon, AO Osunkoya	02/01/2022
Case report: Important considerations for a renal mass on a solitary kidney in an adult with history of childhood wilms tumor. Frontiers in oncology	BN Schmeusser, AR Palacios, E Midenberg, R Nabavizadeh, VA Master, SS Joshi	01/01/2022
Clinic friendly estimation of muscle composition: Preoperative linear segmentation shows overall survival correlated with muscle mass in patients with nonmetastatic renal cell carcinoma. Frontiers in oncology	BN Schmeusser, E Midenberg, AR Palacios, N Vettikattu, DH Patil, A Medline, M Higgins, M Armas-Phan, R Nabavizadeh, SS Joshi, VM Narayan, SP Psutka, K Ogan, MA Bilen, VA Master	01/01/2022
Editorial Comment. The Journal of urology	B Croll, SS Joshi	01/01/2022
Longitudinal impact of bladder cancer diagnosis on common psychiatric disorders. Cancer medicine	IJ Cooke, D Patil, K Bobrek, V Narayan, V Master, M Rapaport, CP Filson, SS Joshi	12/01/2021
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, JM Shabto, S Goyal, Y Liu, TA Olsen, ST Evans, BL Magod, D Ravindranathan, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, SS Joshi, HT Kissick, KE Ogan, WB Harris, O Kucuk, BC Carthon, VA Master, MA Bilen	12/01/2021
Primary urothelial carcinoma of the ureter without concurrent renal pelvic or bladder carcinoma: A contemporary clinicopathologic analysis. Pathology, research and practice	CM Gutierrez, BC Carthon, S Joshi, AO Osunkoya	10/01/2021
Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. Clinical genitourinary cancer	KM Xu, Y Liu, TW Gillespie, AO Osunkoya, B Carthon, MA Bilen, CP Filson, K Ogan, PR Patel, JW Shelton, O Kucuk, S Joshi, AB Jani	08/01/2021
Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on ¹⁸F-Fluciclovine PET/CT Guidance. Journal of nuclear medicine : official publication, Society of Nuclear Medicine	OA Abiodun-Ojo, AB Jani, AA Akintayo, OO Akin-Akintayo, OA Odewole, FI Tade, SS Joshi, VA Master, B Fielder, RK Halkar, C Zhang, S Goyal, MM Goodman, DM Schuster	08/01/2021
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Journal for immunotherapy of cancer	JT Brown, Y Liu, JM Shabto, D Martini, D Ravindranathan, EE Hitron, GA Russler, S Caulfield, L Yantorni, SS Joshi, H Kissick, K Ogan, B Nazha, BC Carthon, O Kucuk, WB Harris, VA Master, MA Bilen	07/01/2021
Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. Cancer	MI Higgins, DJ Martini, DH Patil, R Nabavizadeh, S Steele, M Williams, SS Joshi, VM Narayan, A Sekhar, SP Psutka, K Ogan, MA Bilen, VA Master	06/15/2021
¹⁸F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet (London, England)	AB Jani, E Schreibmann, S Goyal, R Halkar, B Hershatter, PJ Rossi, JW Shelton, PR Patel, KM Xu, M Goodman, VA Master, SS Joshi, O Kucuk, BC Carthon, MA Bilen, OA Abiodun-Ojo, AA Akintayo, VR Dhere, DM Schuster	05/22/2021
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	JT Brown, Y Liu, JM Shabto, DJ Martini, D Ravindranathan, EE Hitron, GA Russler, S Caulfield, LB Yantorni, SS Joshi, H Kissick, K Ogan, WB Harris, BC Carthon, O Kucuk, VA Master, MA Bilen	05/01/2021
Minimizing opioid consumption following robotic surgery. Translational andrology and urology	R Talwar, SS Joshi	05/01/2021
Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. Urologic oncology	G Marra, RJ Karnes, G Calleris, M Oderda, P Alessio, A Palazzetti, A Battaglia, F Pisano, S Munegato, F Munoz, C Filippini, U Ricardi, E Linares, R Sanchez-Salas, S Goonewardene, P Dasgupta, B Challacombe, R Popert, D Cahill, D Gillatt, R Persad, J Palou, S Joniau, S Smelzo, T Piechaud, A Taille, M Roupret, S Albisinni, R van Velthoven, A Morlacco, S Vidit, G Gandaglia, A Mottrie, J Smith, S Joshi, G Fiscus, A Berger, M Aron, A Abreu, IS Gill, H Van Der Poel, D Tilki, D Murphy, N Lawrentschuk, J Davis, P Gontero	05/01/2021
Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. Clinical and translational radiation oncology	JR Janopaul-Naylor, J Zhong, Y Liu, C Zhang, AO Osunkoya, SS Joshi, MA Bilen, B Carthon, O Kucuk, LM Hartsell, J Shelton, AB Jani	01/01/2021
Editorial: 3D Cell Culture Systems for Cardiovascular Tissue Engineering: In vitro Modelling and in vivo Regenerative Therapies. Frontiers in cardiovascular medicine	S Joshi, WH Lee, P Chen, V Serpooshan, H Yang	01/01/2021
Editorial Comment. The Journal of urology	R Nabavizadeh, SS Joshi	01/01/2021
Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical genitourinary cancer	SH Patel, RG Uzzo, A Larcher, B Peyronnet, BR Lane, D Pruthi, M Reddy, U Capitanio, S Joshi, S Noyes, A Eldefrawy, F Ghali, MF Meagher, ZA Hamilton, K Yim, R Nasseri, AW Bradshaw, S Dey, S Kirmiz, F Wan, MA Liss, K Bensalah, F Montorsi, IH Derweesh	12/01/2020
Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (¹⁸F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer. International journal of radiation oncology, biology, physics	A Jani, E Schreibmann, S Goyal, H Raghuveer, B Hershatter, PJ Rossi, JW Shelton, PR Patel, KM Xu, M Goodman, V Master, SS Joshi, O Kucuk, B Carthon, MA Bilen, S Cooper, B Fielder, O Abiodun-Ojo, VR Dhere, DM Schuster	12/01/2020

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	03/15/2025	Very understanding to my concers
One star One star One star One star One star	03/12/2025	Dr. Joshi is an outstanding and caring physician!
One star One star One star One star One star	02/22/2025	All good thanks
One star One star One star One star One star	02/21/2025	I am grateful for the medical care I received
One star One star One star One star One star	01/31/2025	Dr. Joshi was Outstanding in all ways
One star One star One star One star One star	01/17/2025	Absolutely superb experience
One star One star One star One star One star	01/10/2025	Dr. Joshi and his team are the best.
One star One star One star One star One star	01/05/2025	Dr Joshi did an excellent of presenting the nature of my cancer, and options available to me. I am now very comfortable with my treatment plan and have full confidence in him and Emory.
One star One star One star One star One star	01/03/2025	Dr Joshi provides carefully thought out expert care paying respectful attention to my questions and wishes.
One star One star One star One star One star	12/29/2024	Excellent provider. Knowledgeable. Able to explain aspects of disease and treatment effectively.
One star One star One star One star One star	12/27/2024	Dr Joshi was patient & compassionate during this visit.
One star One star One star One star One star	12/12/2024	Dr Joshi feels like a caring partner. He shows me respect and I have respect and trust in him.
One star One star One star One star Empty star	11/22/2024	Good
One star One star One star One star One star	11/02/2024	GOOD
One star One star One star One star One star	10/25/2024	Doc Joshi was professional and engaging. I felt confident he was concerned about my well-being.
One star One star One star One star One star	09/13/2024	Very caring
One star One star One star One star One star	09/12/2024	Dr. Joshi was great
One star One star One star One star One star	09/12/2024	Dr. Joshi is an excellent doctor. He maintains a high degree of professionalism and has an excellent bedside manner. I highly recommend him.
One star One star One star One star One star	09/05/2024	Thank you for listening and taking the time to explain the results of my current issues.
One star One star One star One star One star	09/05/2024	Both knowledgeable and excellent way of expressing that knowledge with care and concern
One star One star One star One star One star	08/27/2024	I love the place awesome doctors and nurses
One star One star One star One star One star	08/16/2024	Excellent explanation of everything needed to be discussed
One star One star One star One star Empty star	08/10/2024	I'm not sure if I saw an NP or PA prior to seeing the doctor. She suggested that the pain I was feeling might have been a phantom pain, or not real. I didn't like that. As women, sometimes our concerns are not taken seriously, and this was coming from a woman.
One star One star One star One star One star	08/08/2024	Very satisfied with my encounter with the entire team
One star One star One star One star One star	07/25/2024	Excellent example for all clinicians in the way the appointment proceeded from beginning to end.
One star One star One star One star One star	06/09/2024	Dr Joshi took time to explain my results and gave me all options. He listened and showed genuine concern. I also liked the other doctor who assisted him.
One star One star One star One star One star	05/30/2024	Dr. Joshi is professional and prudent.
One star One star One star One star One star	05/23/2024	Dr Joshi was very personable and caring and took a lot of time with me
One star One star One star Empty star Empty star	05/16/2024	Very responsive to my primary concern of having a cancer handled competently However there are some unintended consequences which are troubling me which seems to less important to him
One star One star One star One star One star	05/10/2024	I was very comfortable with Dr Joshi